含顺铂方案治疗70岁以上晚期非小细胞肺癌患者

Cisplatin-based Combined Chemotherapy in Patients Aged Above 70 Years with Advanced Non-Small Cell Lung Cancer

目的 评价年龄≥70岁晚期非小细胞肺癌(NSCLC)患者接受以顺铂为基础的联合化疗的疗效和毒副反应。 方法 年龄≥70岁初治的晚期NSCLC患者(ⅢB和Ⅳ期) 32例,接受吉西他滨或长春瑞滨或紫杉醇联合顺铂方案治疗。 结果 全组31例可评价客观疗效。完全缓解2例,部分缓解11例,客观有效率4 2 %。最常见的毒副反应为骨髓抑制,Ⅲ～Ⅳ度白细胞、血小板下降及贫血的发生率分别是2 8.1%、0、0 ,粒细胞缺乏所致发热2例;无化疗相关死亡。中位随访时间13个月。中位生存期9.5个月。 结论 年龄≥70岁的晚期NSCLC患者可以耐受以顺铂为基础的联合化疗。

Objective This study was to evaluate the toxicity and efficacy of a cisplatin-based combined chemotherapy in patients with advanced non-small cell lung cancer(NSCLC) aged above 70 years. Methods 32 chemotherapy-naive patients aged above 70 years with stage ⅢB or Ⅳ of non-small cell lung cancer were enrolled. All the patients received cisplatin-based combined chemotherapy:paclitaxel with cisplatin or vinorelbine with cisplatin or gemcitabine with cisplatin. Results 32 patients were evaluated for toxicity and 31 for response. 2 patients responded for complete remission(6.5%) and 11 patients responded with partial remission(35.4%). The objective response rate(ORR) was 42%. Myelosuppression toxicity was major side effect . The rates of Ⅲ～Ⅳ degree of leucocytopenia, thrombocytopenia and anemia were 28.1%, 0%, 0%,respectively. Two cases of febrile neutropenia during chemotherapy,no chemotherapy related death was found. The overall medication follow-up was 13 months. The median survival time was 9.5 months. Conclusion Patients aged above 70 years with advanced non-small cell lung cancer can tolerace to cisplatin-based combined chemotherapy.